Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is a holding company of a group of companies (the Group) whose principal activity is the early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. Designed as a simple blood test, it enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Contact
c/o Ampa Holdings LLP
32 London Bridge Street
Level 19, The Shard
LondonSE1 9SG
GBRT: +44 2039346630
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 23,076.96 | 142.28 | 0.62% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,527.74 | 380.10 | -0.60% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,641.59 | 16.43 | -0.45% |